Program
CS32582
A development code. Also written as “CS32582 capsule(low dose)”, “CS32582 capsule(medium dose)” and “CS32582 capsule(high dose)”.
Its studies are mostly in Psoriasis, led by Chipscreen Biosciences.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Chipscreen Biosciences | 21 open or running | phase 2since Aug 11, 2025 | Jan 16, 2024 | Sep 18, 2027phase 2 · NCT07129382 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 16, 2024First study: phase 1 study in HealthyFirst studyNCT06224595 · 112 enrolled · China
- Aug 11, 2025Phase 2 study in Plaque PsoriasisNCT07129382 · 220 planned · China
Ahead
- Sep 18, 2027Primary completion: phase 2 study in Plaque PsoriasisNCT07129382
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07129382Plaque Psoriasis · China | 2 | Recruiting | Sep 18, 2027 | 220 |
| NCT06224595Healthy · China | 1 | Completed | Nov 27, 2024 | 112 |
How it is read
Names in the registry
- “CS32582 capsule(low dose)”, 1 entry
- “CS32582 capsule(medium dose)”, 1 entry
- “CS32582 capsule(high dose)”, 1 entry
- “CS32582 capsule”, 1 entry
Codes read as this program: CS32582.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.